Bill Sellers, head of Broad’s Cancer Program, talks about how to discover new classes of genetic dependencies that could move therapies closer to curing cancer patients.
Researchers at Broad and MIT report the first injectable “priming agents” for liquid biopsy, which increased circulating tumor DNA by more than 10-fold in mice.
By adapting virus-like particles to carry the machinery for a type of gene editing called prime editing, scientists have corrected disease-causing mutations in animals and increased editing efficiency.